Last kr564.50 SEK
Change Today -6.50 / -1.14%
Volume 341.6K
As of 9:39 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/2/15 - kr597.50
52 Week Low
03/25/14 - kr407.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZN) Key Developments

AstraZeneca PLC Presents at Bank of America Merrill Lynch 2015 EMEA DCM and Treasury Conference, Mar-05-2015 02:40 PM

AstraZeneca PLC Presents at Bank of America Merrill Lynch 2015 EMEA DCM and Treasury Conference, Mar-05-2015 02:40 PM. Venue: Intercontinental London Park Lane, 1 Hamilton Place, London W1J 7QY, United Kingdom. Speakers: Steve Williamson, Vice President, Cash Generation.

AstraZeneca to Collaborate with Cambridge Judge Business School

AstraZeneca and Cambridge Judge Business School announce collaboration to identify and support biotech start-ups AstraZeneca and the Cambridge Judge Business School at the University of Cambridge announced an agreement to deliver a new Accelerate Cambridge Life Sciences programme at the business school which will identify, train and mentor start-up ventures in the life sciences. The partnership underlines the commitment of both AstraZeneca and Cambridge Judge Business School to scientific enterprise and innovation in the Cambridge area where AstraZeneca is building a new global R&D centre and corporate headquarters, and where Cambridge Judge Business School plans to expand its historic building space. It also reinforces AstraZenecas long-term commitment to supporting bioscience research in the UK. Christoph Loch, director of Cambridge Judge Business School.

AstraZeneca Enters into Research Collaboration with Orca Pharmaceutical for Autoimmune Diseases

AstraZeneca has entered into a research collaboration with compatriot Orca Pharmaceuticals, develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR) for treating autoimmune diseases. The three-year collaboration would involve AstraZeneca gaining access to Orca's ROR inhibitors and incorporating these into its in-house programme, with scientists from both companies jointly working on progressing the programme. On the completion of the collaboration, AstraZeneca will retain the option for acquiring Orca compounds.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:SS kr564.50 SEK -6.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.14 USD +0.2802
Biogen Idec Inc $421.90 USD -3.71
Celgene Corp $119.66 USD -1.05
Eli Lilly & Co $69.46 USD -1.13
Novo Nordisk A/S kr320.70 DKK +2.70
View Industry Companies

Industry Analysis


Industry Average

Valuation AZN Industry Range
Price/Earnings 69.2x
Price/Sales 3.3x
Price/Book 4.3x
Price/Cash Flow 69.2x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at